Urinary Cannabinoid Detection Times After Controlled Oral Administration of [[Delta].Sup.9]-Tetrahydrocannabinol to Humans (Drug Monitoring and Toxicology) (Clinical Report) Urinary Cannabinoid Detection Times After Controlled Oral Administration of [[Delta].Sup.9]-Tetrahydrocannabinol to Humans (Drug Monitoring and Toxicology) (Clinical Report)

Urinary Cannabinoid Detection Times After Controlled Oral Administration of [[Delta].Sup.9]-Tetrahydrocannabinol to Humans (Drug Monitoring and Toxicology) (Clinical Report‪)‬

Clinical Chemistry 2003, July, 49, 7

    • 2,99 €
    • 2,99 €

Beschreibung des Verlags

[[Delta].sup.9]-Tetrahydrocannabinol (THC)6 is the major psychoactive cannabinoid in the marijuana plant Cannabis sativa. Clinical marijuana smoking studies have characterized the urinary pharmacokinetics of THC after inhalation (1-6); ingestion of cannabis has been investigated to a lesser extent (7-11). Since the mid-1990s, food products derived from cannabis plants and advertised as nutritional supplements have been available in the US; one such item is hemp seed oil. Manufacturers suggest that hemp oil is of value as a nutritional supplement because of its high concentration of the essential fatty acids [omega]-linolenic and linoleic acid. Although the hemp seed kernel does not have a substantial THC concentration, hemp oils have been found to contain a wide range of THC concentrations (12-14). The THC content of hemp oil is dependent on the effectiveness of seed cleaning and drying procedures and oil filtration processes. THC contamination originates from plant resin covering the surrounding seed hull. Ingestion of these products may produce positive urine drug tests (13, 15). This has led to questions about the validity of urine drug tests intended to deter drug use in treatment, workplace, criminal justice, and military programs. Several studies have reported that ingestion of hemp oil causes positive urine tests for cannabinoids (12, 16-18). Lehmann et al. (12) reported THC concentrations of 3-1500 [micro]g/g in 25 hemp oil samples. Six individuals ingested one or two tablespoons of hemp oil containing 1500 [micro]g/g THC (11 and 22 g of hemp oil, or ~16.5-33 mg THC). Positive urine specimens were observed with a 50 [micro]g/L cannabinoid immunoassay cutoff and a 15 [micro]g/L 11-nor-9-carboxy-[[Delta].sup.9]-tetrahydrocannabinol (THCCOOH) gas chromatography-mass spectrometry (GC/MS) cutoff for up to 6 days. Costantino et al. (18) reported that seven individuals ingesting 15 mL of hemp oil of an unknown THC concentration had positive urine drug tests by immunoassay at a cutoff of 20 [micro]g/L for up to 48 h after ingestion. GC/MS analysis of urine specimens for THCCOOH, the primary urinary metabolite of THC, identified concentrations up to 78.6 [micro]g/L. This is substantially above the federally mandated urine THCCOOH confirmation cutoff concentration of 15 [micro]g/L. It is of concern that legitimate consumption of hemp oil may be interpreted as illicit drug exposure and that hemp oil ingestion may be used to conceal illicit cannabis use.

GENRE
Wissenschaft und Natur
ERSCHIENEN
2003
1. Juli
SPRACHE
EN
Englisch
UMFANG
38
Seiten
VERLAG
American Association for Clinical Chemistry, Inc.
GRÖSSE
234,9
 kB

Mehr ähnliche Bücher

Resolving Erroneous Reports in Toxicology and Therapeutic Drug Monitoring Resolving Erroneous Reports in Toxicology and Therapeutic Drug Monitoring
2012
Automated Liquid-Chromatographic Analyzer Used for Toxicology Screening in a General Hospital: 12 Months' Experience (Drug Monitoring and Toxicology) Automated Liquid-Chromatographic Analyzer Used for Toxicology Screening in a General Hospital: 12 Months' Experience (Drug Monitoring and Toxicology)
1997
Therapeutic Drug Monitoring Data (Enhanced Edition) Therapeutic Drug Monitoring Data (Enhanced Edition)
2019
Drug Disposition and Pharmacokinetics Drug Disposition and Pharmacokinetics
2011
Standards of Laboratory Practice: Analgesic Drug Monitoring (Nacb Symposium) Standards of Laboratory Practice: Analgesic Drug Monitoring (Nacb Symposium)
1998
Biotin and Other Interferences in Immunoassays (Enhanced Edition) Biotin and Other Interferences in Immunoassays (Enhanced Edition)
2019

Mehr Bücher von Clinical Chemistry

Highly Sensitive Immunoprecipitation Method for Extracting and Concentrating Low-Abundance Proteins from Human Serum (Technical Briefs) Highly Sensitive Immunoprecipitation Method for Extracting and Concentrating Low-Abundance Proteins from Human Serum (Technical Briefs)
2005
Longitudinal Concentrations of Vitamin [B.Sub.12] and Vitamin [B.Sub.12]-Binding Proteins During Uncomplicated Pregnancy (General Clinical Chemistry) (Clinical Report) Longitudinal Concentrations of Vitamin [B.Sub.12] and Vitamin [B.Sub.12]-Binding Proteins During Uncomplicated Pregnancy (General Clinical Chemistry) (Clinical Report)
2002
Multicenter Characterization and Validation of the Intron-8 Poly(T) Tract (IVS8-T) Status in 25 Coriell Cell Repository Cystic Fibrosis Reference Cell Lines for Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene Mutation Assays (Technical Briefs) Multicenter Characterization and Validation of the Intron-8 Poly(T) Tract (IVS8-T) Status in 25 Coriell Cell Repository Cystic Fibrosis Reference Cell Lines for Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene Mutation Assays (Technical Briefs)
2004
Immunoassay Standardization: Is It Possible, Who Is Responsible, Who Is Capable?(Opinion) (Clinical Report) Immunoassay Standardization: Is It Possible, Who Is Responsible, Who Is Capable?(Opinion) (Clinical Report)
2001
A Conversation with Elizabeth Blackburn (Interview) A Conversation with Elizabeth Blackburn (Interview)
2009
The Evolution of Immunoassay As Seen Through the Journal Clinical Chemistry (Aacc 50th Years Anniversary Retrospective) The Evolution of Immunoassay As Seen Through the Journal Clinical Chemistry (Aacc 50th Years Anniversary Retrospective)
1998